Article
PRISM hepatitis B surface antigen detection of hepatits B virus minipool nucleic acid testing yield samples.
Transfusion - 1 Jul 2008
Linauts Sandy, Saldanha John, Strong D Michael
Abstract excerpt
BACKGROUND: Hepatitis B virus (HBV) residual risk has been estimated at 1:63,000-1:205,000 and introduction of more sensitive serological tests and nucleic acid testing (NAT) would reduce that risk. Sensitivity of the recently licensed Abbott PRISM hepatitis B surface antigen (HBsAg) CLIA and minipool (MP) HBV NAT has been described as comparable and thus the need for HBV NAT has not been compelling. In this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
